Jay R. Deshmukh and Joshua A. Whitehill Co-Author “After Lull in Biosimilar IP Litigation, 2021 Could Bring Influx”

Jay R. Deshmukh and Joshua A. Whitehill Co-Author “After Lull in Biosimilar IP Litigation, 2021 Could Bring Influx”

Kasowitz Benson Torres partner Jay R. Deshmukh and special counsel Joshua A. Whitehill have co-authored “After Lull in Biosimilar IP Litigation, 2021 Could Bring Influx,” published in Law360.  In the article, the authors examine the state of U.S. biosimilar approvals by the U.S. Food and Drug Administration under the Biologics Price Competition and Innovation Act and ensuing patent litigation actions.  They also discuss why the dearth of new approvals and litigation in 2020 does not suggest a waning interest in biosimilars, but signals that there is an upcoming wave of biosimilars.

Read the article in its entirety.

Jay R. Deshmukh’s practice focuses on complex intellectual property and patent infringement cases that include Hatch-Waxman Act and biosimilar litigation.  He regularly counsels international generic drug makers on product launches and defends clients against suits from brand-name manufacturers.  Prior to joining Kasowitz, Mr. Deshmukh served as Senior Vice President of Global IP at Ranbaxy Laboratories where he was responsible for the creation of the company’s global intellectual property department.

Joshua A. Whitehill represents life science clients in intellectual property and patent infringement disputes involving small molecules and biological products, including Hatch-Waxman Act and biosimilar litigation.  He has represented clients in patent disputes involving drugs for oncology, immunology, gastroenterology, HIV, diabetes and cardiovascular disorders, as well as gene-editing technologies, medical devices, and vaccines.